Core Viewpoint - Shenzhen Hanyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Hanyu Pharmaceutical") expects significant revenue growth in 2025, with projected revenue between 950 million to 980 million yuan, representing an increase of 60.96% to 66.05% year-on-year, and a net profit of 40 million to 50 million yuan, marking a turnaround from losses in the previous year [1] Group 1: Financial Performance - The company anticipates 2025 revenue of 950 million to 980 million yuan, a year-on-year growth of 60.96% to 66.05% [1] - Net profit is projected to be between 40 million to 50 million yuan, indicating a return to profitability [1] Group 2: Business Development - The growth in revenue is driven by the synergy between international formulations and active pharmaceutical ingredients, which are core engines of revenue growth [1] - The CRDMO (Contract Research, Development, and Manufacturing Organization) business is being actively advanced, contributing to the company's growth strategy [1] Group 3: Research and Innovation - Hanyu Pharmaceutical maintains a strong focus on innovation, with high R&D investment aimed at developing peptide innovative drugs, complex formulations, and cutting-edge technology platforms [1] - Significant progress has been made in multiple research projects, including the three-target innovative drug HY3003 and semaglutide, reinforcing the company's technological barriers [1] Group 4: Strategic Partnerships - The company is expanding its growth avenues through CRDMO business, leveraging its multi-national GMP certification and full industry chain capabilities [1] - Collaborations with companies like Carbon Cloud Peptide and Borui Pharmaceutical have been deepened, covering projects in areas such as antimicrobial peptides and oral peptides, successfully transforming technical accumulation into systematic service output capabilities [1]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has announced additional requirements for the overseas listing application of Macao, focusing on the legality and compliance of its capital increases and share transfers, as well as the verification of its major shareholders and their investment structures [1][3] Group 1: Regulatory Requirements - CSRC requires Macao to provide detailed explanations regarding past capital increases and share transfer pricing, including the basis for pricing and fairness, as well as compliance with capital contribution obligations [1] - The company must also clarify the legality of its establishment and historical share changes, supported by conclusive legal opinions from lawyers [1] - Additional scrutiny is required on the investment structures of major shareholders, including the identification of ultimate beneficial owners and any potential legal restrictions on shareholding [1][2] Group 2: Business Operations - Macao's subsidiaries are required to report on the progress of land delivery and registration of state-owned land use rights [2] - The company must detail its business scope, including medical research, clinical trial services, and cell technology development, confirming whether it has obtained necessary qualifications and permits [2] - The company is also required to ensure compliance with foreign investment regulations before and after the proposed public offering [2] Group 3: Product Development - Macao is positioned as a platform biotechnology company focused on the innovation and development of next-generation bispecific/multispecific peptide drugs, with its core product MT1013 being a pioneering dual-target receptor agonist peptide drug [3] - MT1013 is primarily developed for the treatment of secondary hyperparathyroidism (SHPT) and is planned to expand its indications to include conditions like chronic kidney disease-mineral and bone disorder (CKD-MBD) with osteoporosis [4] - As of September 22, 2025, MT1013 has completed its Phase II clinical trial for SHPT and has entered a Phase III clinical trial using cinacalcet as a positive control [4]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional documentation from Maike Auto regarding its overseas listing application, focusing on capital contributions, share transfers, and compliance with regulations [1][2] Group 1: Regulatory Requirements - CSRC requires Maike Auto to clarify the pricing and fairness of past capital increases and share transfers, as well as confirm whether capital contributions have been fully paid and if there are any breaches of capital obligations [1] - The company must provide legal opinions on the ownership structure of major shareholders and whether any entities are prohibited from holding shares under relevant laws [1][2] Group 2: Company Overview - Maike Auto is a platform-based biotechnology company focused on the innovation and development of next-generation bispecific/multispecific peptide drugs, with its core product MT1013 being the world's first dual-target receptor agonist peptide drug [3] - MT1013 is primarily developed for the treatment of secondary hyperparathyroidism (SHPT) and plans to expand its indications to include conditions like chronic kidney disease-mineral and bone disorder (CKD-MBD) with osteoporosis [3] - As of September 22, 2025, MT1013 has completed its Phase II clinical trial for SHPT and is currently in a Phase III trial using cinacalcet as a positive control [3]

Core Viewpoint - Hanyu Pharmaceutical has signed strategic investment and cooperation agreements with Shenzhen Carbon Cloud Peptide Pharmaceutical Technology Co., Ltd to enhance collaboration in peptide drug development and industrialization [1][2] Group 1: Agreements and Collaborations - The agreements include a strategic investment in Carbon Cloud Peptide and a strategic cooperation for CRDMO services in innovative drugs [1] - Previous collaboration began with a framework agreement in 2024, focusing on leveraging Hanyu's capabilities in peptide drug industrialization and Carbon Cloud's advanced technology in peptide screening using AI [1][2] - A joint development agreement for a GLP-1R/GIPR/GCGR triple agonist innovative drug project was established in May 2025, laying a solid foundation for further cooperation [1] Group 2: Project Development and Support - Hanyu Pharmaceutical will utilize its CRDMO technical platform and industrialization advantages to support multiple innovative drug projects under Carbon Cloud, including PDC peptide conjugated drugs and AI antibacterial peptides [2] - The cooperation encompasses the entire process from preclinical research to commercialization, covering key aspects such as active pharmaceutical ingredient process optimization, formulation development, quality research, registration, and large-scale production [2] - Industry analysts believe this collaboration will strengthen Hanyu's industrial synergy in the peptide CRDMO service chain and accelerate the commercialization of innovative products for Carbon Cloud, achieving resource sharing and complementary advantages [2]